Skip to main content
. 2023 Feb 22;8(4):e156643. doi: 10.1172/jci.insight.156643

Figure 4. Time to termination of adalimumab treatment due to ineffectiveness, stratified by the number of HLA-DRB1 protective residues present.

Figure 4

(A) Within the discovery cohort (individuals sampled 6–36 months after treatment initiation, n = 784). (B) Within the adalimumab treatment duration cohort (individuals for whom clinical data but no ADA status was available, n = 716). Kaplan-Meier survival analysis was used. Red: 0 protective residues. Blue: 1 protective residue. Green: 2 protective residues.